Canaccord Genuity downgrades Dice Therapeutics to 'hold' with a price target of $48.00

  • Investing.com
Canaccord Genuity downgrades Dice Therapeutics to 'hold' with a price target of $48.00

An analyst from Canaccord Genuity downgraded Dice Therapeutics (NASDAQ: DICE ) from 'buy' to 'hold' with a price target of $48.00 from a prior price target of %currency%%price%.

Prior to this rating, Dice Therapeutics had 10 buy ratings, 1 hold ratings, and 0 sell ratings.

For consensus analyst estimates and price targets on Dice Therapeutics, click here. For more news on Dice Therapeutics, click here.

Dice Therapeutics's stock price closed at $33.85. They are down -0.76% in the last month and up 217.62% in the last 12 months.

According to Investing Pro, Dice Therapeutics's fair value is $25.28, a downside of 25.32%. Dice Therapeutics's fair value comes with a high degree of uncertainty, according to InvestingPro.

Check out Dice Therapeutics's recent earnings performance and financials here.

Drop an image here or Supported formats: *.jpg, *.png, *.gif up to 5mb

Error: File type not supported

Drop an image here or

100

Related Articles